TORONTO (Reuters) - Stem Cell Therapeutics, a Canadian biotechnology company, said on Friday it would remove its senior executives to save money after the lead study of a stroke treatment failed to meet targets.
TORONTO (Reuters) - Stem Cell Therapeutics, a Canadian biotechnology company, said on Friday it would remove its senior executives to save money after the lead study of a stroke treatment failed to meet targets.